251 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release http://www.zacks.com/stock/news/392470/incyte-incy-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release?cid=CS-ZC-FT-392470 Apr 23, 2019 - Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap http://www.zacks.com/stock/news/390936/the-zacks-analyst-blog-highlights-commscope-ceridian-hcm-cabot-oil-gas-incyte-and-snap?cid=CS-ZC-FT-390936 Apr 23, 2019 - The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? http://www.zacks.com/stock/news/390180/exact-sciences-exas-to-post-q1-earnings-whats-in-store?cid=CS-ZC-FT-390180 Apr 22, 2019 - During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season? http://www.zacks.com/stock/news/390036/is-a-beat-in-store-for-abbvie-abbv-this-earnings-season?cid=CS-ZC-FT-390036 Apr 22, 2019 - Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
5 Must-Buy Stocks Amid Exaggerated Economic Slowdown http://www.zacks.com/stock/news/389800/5-must-buy-stocks-amid-exaggerated-economic-slowdown?cid=CS-ZC-FT-389800 Apr 22, 2019 - The recently released three major economic data of March clearly indicated that the inherent strength of the economy remains intact.
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains http://www.zacks.com/stock/news/366679/4-toxic-stocks-to-abandon-or-sell-short-for-solid-gains?cid=CS-ZC-FT-366679 Mar 29, 2019 - Overpriced toxic stocks are generally susceptible to outside shocks and burdened with a huge amount of debt.
Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica http://www.zacks.com/stock/news/359403/zackscom-featured-expert-kevin-matras-highlights-incyte-amc-entertainment-covanta-and-us-silica?cid=CS-ZC-FT-359403 Mar 14, 2019 - Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica
10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run http://www.zacks.com/stock/news/359267/10-stocks-powering-sp-500-etf-in-the-10-year-bull-run?cid=CS-ZC-FT-359267 Mar 13, 2019 - Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains http://www.zacks.com/stock/news/359209/4-toxic-stocks-to-abandon-or-sell-short-for-solid-gains?cid=CS-ZC-FT-359209 Mar 13, 2019 - Overhyped toxic stocks are usually susceptible to external shocks and burdened with huge amount of debt.

Pages: 12345678...26

<<<Page 3>